Christopher Porter

Jul 18, 2024 | nature.com | Olivier Saulnier |Paul Jerard Layug |Kimberly A Aldinger |Christopher Porter |Stephane Richard |Brad Doble | +1 more

AbstractOTX2 is a transcription factor and known driver in medulloblastoma (MB), where it is amplified in a subset of tumours and overexpressed in most cases of group 3 and group 4 MB. Here we demonstrate a noncanonical role for OTX2 in group 3 MB alternative splicing. OTX2 associates with the large assembly of splicing regulators complex through protein–protein interactions and regulates a stem cell splicing program.

Sep 19, 2023 | nature.com | Christopher Porter |Vijay Ramaswamy

AbstractSonic Hedgehog (SHH) medulloblastomas (MBs) exhibit an intermediate prognosis and extensive intertumoral heterogeneity. While SHH pathway antagonists are effective in post-pubertal patients, younger patients exhibit significant side effects, and tumors that harbor mutations in downstream SHH pathway genes will be drug resistant. Thus, novel targeted therapies are needed.